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doi:10.1Objectives: Guidelines recommend antibiotic prophylaxis 60 minutes before skin incision; however, it is un-
clear whether more precise timing would further reduce sternal wound infection. Our objectives were to examine
the relationship between antibiotic timing and infection, test potential efficacy of optimal antibiotic timing in
preventing infection, and determine whether patient comorbidity is related to timing and infection.
Methods: From 1/1/1995–1/1/2008, 28,250 patients underwent 28,702 cardiac surgical procedures involving
a median sternotomy; 85% received only cefuroxime and 15% received only vancomycin prophylaxis. Multi-
variable analysis identified factors associated with infection within each phase, and risk-adjusted optimal timing
was determined using patient data, risk variables, and hypothetical values of antibiotic timing.
Results: Prevalence of sternal wound infection was 2.0% (489 patients) for cefuroxime and 2.3% (101 patients)
for vancomycin. Minimum prevalence for infection was 1.8% observed when cefuroxime was administered 15
minutes before incision; risk increased to 2.2%with administration more than 45 minutes before incision and to
2.8% at 60 minutes before incision. Minimum prevalence of infection in patients who received vancomycin was
1.8% observed with initiation 32 minutes before incision; risk increased to 2.2% for administration 45 minutes
before incision and 3.2% with administration 60 minutes before incision. Simulation for optimal timing found
that it was influenced by phase-specific risk factors.
Conclusions: Refining current antibiotic prophylaxis guidelines may lower sternal wound infections. Antibiotic
administration timing resulting in lowest likelihood for infection varied with antibiotic and patient-specific fac-
tors. Optimal risk-adjusted timing could potentially reduce infections by 9%-31%. (J Thorac Cardiovasc Surg
2012;144:931-7)P
MSupplemental material is available online.Safety for the 30 million Americans who undergo surgical
procedures annually is at the heart of strategies for prevent-
ing surgical site infections. There are guidelines for proper
choice, timing of administration, and duration of prophylac-
tic antibiotics in cardiac surgery, of which optimal timing of
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The Journal of Thoracic and Caprophylactic administration of antibiotics within 60 min-
utes before skin incision; however, it is unclear whether
more precise timing of administration within that period
would be more effective in lowering occurrence of postop-
erative sternal wound infection. The primary objectives
were to examine the relationship between timing of prophy-
lactic antibiotic administration and occurrence of postoper-
ative sternal wound infection and to test the potential
efficacy of optimal timing for choice of antibiotic in pre-
venting infection. Our secondary objective was to deter-
mine whether patient comorbidity was related to optimal
timing of antibiotic administration and subsequent postop-
erative sternal wound infection.PATIENTS AND METHODS
Patients
From January 1, 1995, to January 1, 2008, a total of 28,250 patients un-
derwent 28,702 cardiac surgical procedures involving a median sternotomy
at Cleveland Clinic. Patients who had active endocarditis, surgical ap-
proach without a median sternotomy, lacked documentation for antibiotic
administration, had more than 1 operation on the same date, or who re-
ceived antibiotics other than cefuroxime and vancomycin were excluded
from the analysis (Figure E1). Two study groups consisted of 24,272
(85%) patients who received only cefuroxime and 4430 (15%) who re-
ceived only vancomycin prophylaxis. Baseline characteristics and perio-
perative variables by antibiotic status are presented in Table 1.rdiovascular Surgery c Volume 144, Number 4 931
Abbreviations and Acronyms
BMI ¼ body mass index
COPD ¼ chronic obstructive pulmonary disease
ITA ¼ internal thoracic artery
STS ¼ The Society of Thoracic Surgeons
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Demographics and perioperative variables were extracted from the Car-
diovascular Information Registry and timing of antibiotic administration
from chart abstraction and the Cardiothoracic Anesthesia Registry elec-
tronic anesthesia record (Table 1). The Cleveland Clinic Institutional Re-
view Board approved these registries for use in research, with patient
consent waived.
Of note, our standard protocol for prophylaxis in cardiac surgical pa-
tients included administration of cefuroxime for non–penicillin-allergic pa-
tients (1.5 g every 12 hours3 3 doses); penicillin-allergic patients received
vancomycin prophylaxis (1 g every 12 hours3 3 doses); subsequent to this
study, in 2009, aztreonam 1 g 3 1 dose was added to the vancomycin reg-
imen. Since 2003, we have used preoperative screening for Staphylococcus
aureus carriage with use of mupirocin for decolonization, if positive.1 In
addition, strict attention was directed toward control of perioperative blood
sugar per standardized perioperative protocol.2
End Point
End points of the investigation were occurrence of deep and superficial
sternal wound infection. Case ascertainment done for sternal wound infec-
tion was defined by The Society of Thoracic Surgeons (STS).
Data Analysis
Simple descriptive statistics were used to summarize the data: mean 
standard deviation and 15th/50th/85th percentiles for continuous variables
and frequencies and percentages for categorical variables. Comparisons
were made using the Wilcoxon rank-sum tests and c2 tests, respectively.
Because cefuroxime and vancomycin have different dosing administra-
tion times, all analyses for each were performed separately.
All analyses were performed using SAS statistical software (SAS v9.5,
SAS, Inc, Cary, NC) and R statistical software.3
Missing Data
In this prospective observational data, many baseline variables have
missing data, with the degree ranging from 0% to 17%. Hence, to avoid
eliminating the missing cases in the multivariable analyses, we have used
completed data sets obtained by multiple imputation. It was performed us-
ing theMarkov ChainMonte Carlo4 technique to impute missing values us-
ing 5-fold multiple imputation with PROC MI (SAS v9.1). In the logistic
modeling, for each imputed data set, we estimated regression coefficients
and their variance–covariance matrix. Following Rubin,4 we combined es-
timates from the 5 models using PROC MIANALYZE.
Temporal pattern of prevalence of infection. Using a non-
linear binary logistic regression, we first analyzed the temporal pattern of
the prevalence over the timing of antibiotic (interval from time of incision
to time of antibiotic administration). PROC NLMIXED (SAS, Inc) was
used to identify the additive phases (of timing of antibiotic) in the odds do-
main. Asymmetric 68% confidence intervals for prevalence of infection
(equivalent to1 standard error) were obtained by the bootstrap percentile
method.5
Multivariable analyses. Multivariable analysis of preoperative
variables (Table 1) was performed to identify factors associated with infec-
tion within each phase (see Appendix E1 for details). Variable selection932 The Journal of Thoracic and Cardiovascular Surgwas performed using bootstrap bagging (bootstrap aggregation).6,7 At
each step of the aggregation, the original data set was sampled with
replacement, and using stepwise selection with entry criterion of P ¼ .1
and retention criterion of P ¼.05, variables associated with infection
were identified and stored. These steps were repeated 500 times. All
variables with bootstrap reliability of 50% or more were retained in the
guided analysis.
Optimal timing. Optimal timing was defined as the time of antibiotic
administration when the likelihood of sternal wound infection was lowest.
For each patient, risk-adjusted optimal timing was determined by solv-
ing themultivariable equations using that patient’s actual data, the risk vari-
ables, and hypothetical values of antibiotic timing. We then obtained
optimal timing by identifying the hypothetical time when the predicted
risk of infection was lowest.
RESULTS
Antibiotic Timing
Overall, nearly 90% of patients received antibiotics
within the protocol time frame. However, in the cefuroxime
group, where the protocol is administration within 60 min-
utes before incision, 4.6% received it too early and 3.8%
too late. In the vancomycin group, where the protocol is ad-
ministration within 120 minutes before incision, 0.61% re-
ceived it too early and 10% too late (Figure 1).
Sternal Wound Infection
Overall prevalence of sternal wound infection was 2.1%
(590 patients); superficial wound infection prevalence was
1.3% (379), and deep wound infection 0.74% (211). In-
hospital mortality was higher among patients with a sternal
wound infection than those without, 8.6% versus 1.8%;
P<.0001. Morbidity was substantially greater in patients
with than without sternal wound infections: stroke, 4.1%
versus 1.5%, P<.0001; renal failure, 8.5% versus 1.4%,
P< .0001; respiratory insufficiency, 30% versus 6.1%,
P < .001; and septicemia/sepsis, 26% versus 2.1%,
P<.0001, respectively. Similarly, median length of hospital
stay was 17 days (15th and 85th percentiles ¼ 8 and 36
days) for patients with sternal wound infections versus 6
days (15th and 85th percentiles ¼ 5 and 11 days) for those
without; P<.0001. Among patients who received cefurox-
ime alone, prevalence of sternal wound infection was 2.0%
(489 patients); prevalence with vancomycin alone was
2.3% (101 patients), P ¼ .3.
Timing and Infection
Cefuroxime. Unadjustedminimumprevalence for infection
was 1.8% and observed when cefuroxime was administered
15minutes before surgical incision (Figure 2). Predicted per-
centages of sternal wound infection varied considerably for
antibiotic timing both within protocol guidelines and for pro-
tocol deviations (Table 2). Risk for sternal wound infection
increased when cefuroxime was administered more than 15
minutes before surgical incision, yet within protocol recom-
mendations. Prevalence of infection was 2.2% at 45 minutes
and 2.8% at 60 minutes before skin incision. Protocolery c October 2012
TABLE 1. Patient and perioperative characteristics by antibiotic status
Variable
Vancomycin (total n ¼ 4,430) Cefuroxime (total n ¼ 24,272)
n* No. (%) or mean ± SD n* No. (%) or mean ± SD
Demography
Age (y) 4430 66  12 24,272 65  12
Male 4430 2602 (59) 24,272 17,364 (72)
BMI (kg $ m2) 4426 28  5.7 24,249 28  5.4
Cardiac comorbidity
NYHA functional class III/IV 4429 1613 (36) 24,268 7929 (33)
Emergency operation 4430 82 (1.9) 24,272 326 (1.3)
Previous myocardial infarction 4430 2011 (45) 24,271 11,145 (46)
Complete heart block/pacer (ECG) 4430 186 (4.2) 24,272 816 (3.4)
Reoperation 4430 1163 (26) 24,272 5540 (23)
Coronary artery diseasey
LAD 3508 2416 (69) 19,359 14,005 (72)
LCx 3504 2112 (60) 19,336 12,216 (63)
RCA 3496 2194 (63) 19,321 12,685 (66)
LMT 3497 690 (20) 19,328 3598 (19)
Noncardiac comorbidity
Peripheral arterial disease 4430 2017 (46) 24,272 9716 (40)
COPD 3927 1061 (27) 20,256 4527 (22)
Smoking 4381 2631 (60) 23,996 14,285 (60)
Hypertension 4332 3195 (74) 23,654 16,592 (70)
Treated diabetes 4366 1204 (28) 23,770 5921 (25)
Dialysis 3642 51 (1.4) 20,055 197 (0.98)
Stroke 4430 416 (9.4) 24,272 1918 (7.9)
Bilirubin (mg $ dL1) 3683 0.71  0.56 20,373 0.72  0.63
Blood urea nitrogen (mg $ dL1) 4361 21  11 23,861 20  10
Hematocrit (%) 3844 38  5.4 21,046 39  5.4
Procedure
Aortic valve 4430 1299 (29) 24,272 5978 (25)
Mitral valve 4430 1309 (30) 24,272 6602 (27)
Tricuspid valve 4430 273 (6.2) 24,272 1124 (4.6)
No. of ITA grafts 4430 24,271
0 2143 (48) 10,498 (43)
1 2026 (46) 11,672 (48)
2 261 (5.9) 2101 (8.7)
CABG 4430 3120 (70) 24,272 17,642 (73)
Surgical approach: less invasive incision 4430 488 (11) 24,272 2781 (11)
Support
Cardiopulmonary bypass time (min) 4430 96  47 24,271 95  45
Experience
Date of operation (y)z 4430 6.2  3.4 24,272 5.9  3.7
SD, Standard deviation; BMI, body mass index; NYHA, New York Heart Association; ECG, electrocardiogram; LAD, left anterior descending; LCx, left circumflex; RCA, right
coronary artery; LMT, left main trunk;COPD, chronic obstructive pulmonary disease; ITA, internal thoracic artery;CABG, coronary artery bypass graft. *Patients with data avail-
able. yFifty percent stenosis or more. zInterval from January 1, 1995, to date of operation.
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Mdeviations resulted in the highest prevalence for infection,
with 3.7% when cefuroxime was administered too early,
that is, 75minutes before incision; for administration after in-
cision the prevalence of infection was 2.4%.
A number of perioperative factors were associated with
increased likelihood for postoperative sternal wound infec-
tion (Table E1). The following factors were associated over-
all for the cefuroxime group: diabetes (P<. 0001), stroke
(P ¼ .0003), prior myocardial infarction (P ¼ .0002), pe-
ripheral arterial disease (P ¼ .0002), longer preoperativeThe Journal of Thoracic and Calength of stay (P ¼ .04), operative factors such as mitral
valve procedure (P<.0001), lower preoperative hematocrit
(P ¼ .001), complete heart block (P ¼ .02), and more
internal thoracic artery (ITA) grafts (P<.0001). The pre-
minimum phase risk factors for cefuroxime included history
of chronic obstructive pulmonary disease (COPD)
(P< .0001) and higher blood urea nitrogen (P ¼ .0002).
The post-minimum phase risk factors for cefuroxime in-
cluded larger body mass index (BMI) (P ¼ .0002) and
higher New York Heart Association class (P ¼ .005).rdiovascular Surgery c Volume 144, Number 4 933
FIGURE 1. Distribution of antibiotic timing stratified by antibiotic status
(cefuroxime, gray line; vancomycin, black line). Vertical dashed lines rep-
resent current protocol guidelines for administration.
TABLE 2. Predicted percentages of infection at different antibiotic
timing administration for cefuroxime and vancomycin
Antibiotic
timing (min)
Cefuroxime predicted%
(68% CLs)
Vancomycin predicted%
(68% CLs)
75 3.7 (3.2-4.4) 4.6 (2.5-6.8)
60 2.8 (2.4-3.1) 3.2 (2.1-4.5)
45 2.2 (2.0-2.3) 2.2 (1.6-2.8)
30 1.9 (1.8-2.0) 1.8 (1.5-2.2)
15 1.8 (1.7-2.0) 2.1 (1.8-2.3)
0 (incision) 2.0 (1.8-2.2) 2.6 (2.1-3.0)
15 2.4 (1.9-2.9) 3.3 (2.4-4.0)
CLs, Confidence limits.
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MVancomycin. Antibiotic timing and likelihood for infec-
tion differed between vancomycin and cefuroxime. Unad-
justed minimum prevalence of infection in patients who
received vancomycin was 1.8% observed with antibiotic
administration initiated 32 minutes before surgical incision
(Figure 3). Predicted percentages for development of sternal
wound infection varied considerably within protocol
boundaries and for protocol deviations. Prevalence of infec-
tion was 2.2% for administration 45 minutes before inci-
sion: 3.2% with administration 60 minutes before incision
and 4.6% with administration 75 minutes before incision.
Vancomycin administration after incision resulted in a prev-
alence of infection of 3.3% (Table 2 and Figure 3).Cefuroxime
FIGURE 2. Percentage of postoperative sternal wound infections by time
for cefuroxime antibiotic prophylaxis. Solid line represents estimated per-
centages of infection enclosed within dashed 68% bootstrapped percentile
confidence intervals. Symbols represent data grouped within time frame to
provide a crude verification of model fit. Vertical dashed lines represent
current protocol time frame for administration.
934 The Journal of Thoracic and Cardiovascular SurgRisk factors associated with a higher likelihood of wound
infection in the vancomycin group (Table E2) were diabetes
(P ¼ .007), history of chronic obstructive pulmonary dis-
ease (P ¼ .01), dialysis (P ¼ .03), coronary artery disease
such as left anterior descending (P¼ .01) or left main trunk
disease (P ¼ .02), emergency operation (P ¼ .02), and no
history of hypertension (P ¼ .02). The pre-minimum phase
risk factor for vancomycin was bilateral ITA grafts
(P ¼ .0001). The post-minimum phase risk factors for van-
comycin were higher blood urea nitrogen (P ¼ .07) and
larger BMI (P ¼ .04).
Simulation and Optimal Timing
Cefuroxime. Risk-adjusted optimal timing was defined as
the time of antibiotic administration resulting in the lowest
likelihood for postoperative sternal wound infection. Cefur-
oxime timing varied between 75 minutes before incision to
the time of incision. Mean optimal risk-adjusted time for ce-
furoxime administration was 27 minutes (14 minutes) be-
fore surgical incision. However, optimal timing was
influenced by phase-specific risk factors. In patients with
COPD,mean optimal timing was 18minutes before incision
versus those without COPD, for whom it was 30 minutes.
Patients with greater BMI (>30 kg $ m2) had an optimal
time of cefuroxime administration of 39 minutes versusVancomycin
FIGURE 3. Percentage of postoperative sternal wound infections by time
for vancomycin antibiotic prophylaxis. Format is as in Figure 2.
ery c October 2012
TABLE 3. Risk-adjusted optimal cefuroxime timing and predicted
reduction in sternal wound infection
Group No.
Optimal timing
(min, mean ± SD)
Predicted
reduction (%)*
Overall 24,034 27  14 46 (9.5)
Risk-adjusted individual
patient timingy
— — 85 (18)
COPD 55 (11)
No 17,835 30  12
Yes 6199 18  13
BMI 60 (12)
30 kg $ m2 16,701 21  10
>30 kg $ m2 7333 39  11
COPD and BMI 67 (14)
No COPD
BMI 30 kg $ m2 12,500 24  8.9
BMI>30 kg $ m2 5335 43  10
COPD
BMI 30 kg $ m2 4201 12  9.2
BMI>30 kg $ m2 1998 31  11
SD, Standard deviation; COPD, chronic obstructive pulmonary disease; BMI, body
mass index. *Predicted reduction in sternal wound infection when using optimal tim-
ing. yBased on individual risk-adjusted optimal timing (Figure E2).
TABLE 4. Risk-adjusted optimal vancomycin timing and predicted
reduction in sternal wound infection
Group No.
Optimal timing
(min, mean ± SD)
Predicted
reduction (%)*
Overall 4356 32  10 18 (18)
Risk-adjusted individual
patient timingy
— — 30 (31)
Bilateral ITA 27 (28)
No 4100 34  7.1
Yes 256 1.9  2.4
BMI 18 (18)
30 kg $ m2 2918 29  8.2
>30 kg $ m2 1438 39  11
SD, Standard deviation; ITA, internal thoracic artery; BMI, body mass index. *Pre-
dicted reduction in sternal wound infection when using optimal timing. yBased on
individual risk-adjusted optimal timing (Figure E3).
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Mthose with a BMI of 30 kg $ m2 or less, for whom optimal
time of administration was 21 minutes before incision. Op-
timal time of cefuroxime administration also differed with
combinations of risk factors (Table 3 and Figure E2).
Using the mean risk-adjusted optimal timing of 27 min-
utes for administration of cefuroxime could result in
a 9.5% reduction in postoperative sternal wound infection,
and with consideration of individual optimal antibiotic tim-
ing related to patient-specific risk factors, reductions of up
to 18% could be realized (see Table 3).
Vancomycin. Mean risk-adjusted optimal timing for van-
comycin administration was 32 minutes before incision.
Risk for sternal wound infection was similarly related to
patient-specific factors. Simulation suggested a closer
time for antibiotic administration to incision in patients
with bilateral ITA grafting and greater time from vancomy-
cin administration to incision (39 minutes) for patients with
higher BMI (>30 kg $ m2) (Table 4 and Figure E3).
Overall percent reduction in the prevalence of postoper-
ative sternal wound infection could be achieved with con-
sideration of optimal antibiotic timing and patient-specific
risk factors. For example, use of mean optimal vancomycin
timing could result in an overall 18% reduction in postop-
erative sternal wound infection, and with consideration of
patient-specific risk factors, a 31% reduction in sternal
wound infection could be achieved (see Table 4).
COMMENT
Principal Findings
Prevalence of postoperative sternal wound infection var-
ied considerably when prophylactic administration was
within standard protocol guidelines. Lowest observedThe Journal of Thoracic and Caprevalence for infection was administration to skin incision
time of 19minutes for cefuroxime and 32minutes for vanco-
mycin. Protocol deviations in antibiotic administration in-
creased occurrence of sternal wound infections. By
following mean optimal risk-adjusted timing of antibiotic
administration, potential for reducing the likelihood of ster-
nal wound infection was 9.5% with cefuroxime and 18%
with vancomycin. Furthermore, when patient-specific risk
factors were considered in antibiotic prophylaxis timing, op-
portunity for reducing postoperative sternal wound infection
reached 18% for cefuroxime and 31% for vancomycin.
Recommendations for antimicrobial prophylaxis include
antibiotic administration within 60 minutes of surgical inci-
sion for cephalosporins and within 120 minutes for vanco-
mycin. Intent of guidelines in terms of proper timing of
therapy is to allow time for adequate blood and tissue con-
centrations to exceed minimum inhibitory concentration of
the pathogens, thereby preventing an infection at the surgi-
cal site.8,9 Published guidelines address both timing and
duration of antimicrobial therapy in the surgical setting.10
An investigation of surgical site infections and antibiotics
with shorter administration times reported a trend toward
lower risk when cephalosporins were given within 30 min-
utes of (before) incision time. Infection risk increased as the
time interval between preoperative antibiotic and incision
increased or if antibiotic was administrated after skin inci-
sion. Infection risk after administration of antibiotic within
30 minutes before incision was 1.6% compared with 2.4%
with administration between 31 to 60 minutes before inci-
sion.11 Their data suggested that optimal timing is perhaps
closer to incision, similar to our findings.
In contrast, others have reported that cefuroxime admin-
istration immediately before surgical incision may be less
effective than antimicrobial therapy given between 30 and
60 minutes of incision.12 Differences among reported stud-
ies may be related to patient-specific factors, such as obe-
sity, and factors related to the surgical procedure, such as
use of ITA grafting.rdiovascular Surgery c Volume 144, Number 4 935
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MGarey and colleagues13 examined timing of vancomycin
prophylaxis and risk of surgical site infections in cardiac
surgical patients. Vancomycin administration initiated
within 16 to 60 minutes before surgical incision reduced
the risk of surgical site infections. In a separate investiga-
tion, they demonstrated that optimizing vancomycin admin-
istration before surgical incision could lead to economic
benefits by decreasing surgical site infections and subse-
quent length of hospital stay.14
Risk Factors
Reported prevalence of deep and superficial sternal
wound infections after cardiac surgery range from 0.25%
to 4% and 2% to 6%, respectively.15-22 In coronary
artery bypass grafting, Crabtree and colleagues reported
a 2.2% prevalence of superficial and 1.8% prevalence of
deep sternal wound infections. Risk factors for superficial
infections were higher BMI, female gender, active
smoking, use of bilateral ITA grafts, and transfusion. Risk
factors for deep sternal wound infections included
increasing BMI, diabetes, and platelet transfusion.20 Our in-
vestigation and others have similarly reported that patient
demographics, comorbidity, and operative factors are re-
lated to an increased risk for developing sternal wound
infections.18,19,23
Clinical Implications
Morbid complications related to sternal wound infections
are significant, with mortality estimates of 5% to
23%.15,20,24,25 From STS data, Fowler and colleagues16 re-
ported an overall 3.5% occurrence of major infection,
among which 25% were due to mediastinitis (0.6% over-
all). Patients with major postoperative infections had higher
mortality and longer postoperative length of stay than pa-
tients without major infections. Braxton and colleagues
similarly reported increased mortality in patients who de-
velopedmediastinitis following isolated coronary artery by-
pass grafting17 and, in a separate investigation, reported
lower 1- and 4-year survival.26
Other investigators have suggested an opportunity to re-
duce occurrence of sternal wound infections by targeting
patient-specific factors, such as weight reduction and smok-
ing cessation.15 Our results offer additional opportunity for
reducing infection by refining current guideline recommen-
dations. The best we can do with perfect simulation is to de-
termine whether antibiotic administration should be closer
or further from skin incision to get the best results. We dem-
onstrated a ‘‘U-shaped’’ relationship whereby risk for infec-
tion increased outside the recommended boundaries. The
concept of optimal time exists only when the ideal is within
some boundary limits, that is, either too early or too late.
Why risk for infection increases when antibiotics are ad-
ministered more than 60 minutes before incision is unclear,
because antibiotic tissue levels should be sufficient until the936 The Journal of Thoracic and Cardiovascular Surgnext dosing interval (hours later). Our findings demonstrate
that there may be an optimal time, yet also that patient-
specific risk factors should be considered in this population.
Reality of findings about when to administer antibiotics
suggests clinicians think about optimal antibiotic timing
in the context of patient-specific risk factors. For example,
in patients with higher BMI (>30 kg $m2), simulation sug-
gests a beneficial effect of shifting antibiotic administration
to allow for more time between administration and incision,
possibly allowing for adequate tissue antimicrobial activity.
Limited pharmacokinetic studies have been performed in
obese patients, for whom many factors may affect antimi-
crobial concentrations. Standard doses of cephalosporins
may result in low serum and tissue levels in these patients;
increasing cefazolin from 1 to 2 g has been reported to re-
duce their surgical site infections (16% to 5.6%).27 Edmis-
ton and colleagues28 examined patients undergoing open or
laparoscopic gastric bypass who received cefazolin 2 g in-
travenously 30 to 60 minutes before incision and reported
decreasing concentrations of cefazolin in the serum, skin,
adipose tissue, and omental tissue with increasing BMI.
When considering patient-specific risk factors such as
BMI, modifications in cefuroxime administration could re-
duce infection by 12%. Similarly, with use of ITA grafting,
special consideration in vancomycin antibiotic timing could
result in reductions in the likelihood of infection by 28%.
Limitations
Our primary outcome was development of deep and su-
perficial wound infections identified during the primary
hospitalization. Sternal wound infections becoming mani-
fest after discharge were not included because longitudinal
follow-up data for these were unavailable. Lack of this in-
formation underestimates occurrence of sternal wound in-
fections. The Cardiothoracic Surgical Trials Network
recently completed one of the first in-depth investigations
on infectious complications after cardiac surgery. Patients
were followed up to 60 days from index surgical procedure
for development of infections. A number of postoperative
infections occurred after discharge and varied depending
on the individual infectious complications. Among patients
in whom mediastinitis developed after surgery, approxi-
mately 50% were identified after discharge.29 Our sample
is based on the data that we and the STS currently have
available for reporting infectious complications. We believe
that the infections are initiated in the perioperative period
yet manifest either early or late. We do not have data to sug-
gest that infections manifesting later after discharge are dif-
ferent from those manifesting in-hospital after the index
surgery. We used STS rather than Center for Disease Con-
trol definitions for sternal wound infections. In addition,
this investigation was a prospective cohort investigation,
and unmeasured confounding variables could have affected
study results.ery c October 2012
Koch et al Perioperative Management
P
MCONCLUSIONS
Sternal wound infections are a dreaded complication of
cardiac surgery and portend serious morbidity. Patient
safety depends on seizing the limited opportunity for con-
trol of preoperative risk. Our data demonstrate the impor-
tance of refining process-of-care factors such as antibiotic
timing. Optimal timing with consideration of patient-
specific risk factors reduced the likelihood of developing
postoperative sternal wound infections.
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APPENDIX E1.
Nonlinear Multivariable Logistic Regression
We have used a 2-step modeling strategy to quantify the re-
lationship between timing of antibiotic administration and
infection and baseline patient–procedure characteristics
and infection. In the first step, because the descriptive inves-
tigations revealed a skewed U-shaped relationship between
timing of antibiotic administration and infection, we used
additive nonlinear equations and logistic regression to iden-
tify the decreasing and increasing phases (of timing of anti-
biotics). We call these pre-minimum and post-minimum
phases.
It is believed that there may be some baseline variables
that influence (or in other words, interact with the timing
of antibiotics) the infection only in the pre-minimum phase,
some only in the post-minimum phase, and some indepen-
dently of the phases (of the timing of antibiotics). Hence,
in the second step, we performed multivariable logistic re-
gression simultaneously to identify the 3 sets of patient–
procedure characteristics. The motivation for this analytical
strategy was similar to that used by Blackstone, Naftel, and
TurnerE1 to model the time-related phases of hazard of
time-to-event data.
E-Reference
E1. Blackstone EH, Naftel DC, Turner ME Jr. The decomposition of time-varying
hazard into phases, each incorporating a separate stream of concomitant informa-
tion. J Am Stat Assoc. 1986;81:615-24.
Patients had cardiac surgery
(Jan 1995–Jan 2008)
(n = 33,077)
Eligible for analyses
(n = 30,399)
Analyzed: (n = 24,272)
Antibiotic: Cefuroxime 
alone
Analyzed: (n = 4,430)
Antibiotic: Vancomycin 
alone
Not analyzed: (n = 1,697)
Antibiotic: Other
Excluded (n = 2,678)
● Active endocarditis
● Antibiotic not documented
● More than one surgery on same day
● Cardiac surgical patients without a 
sternal incision
FIGURE E1. CONSORT diagram of patient population.
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FIGURE E2. Distribution of patient-specific optimal timing in cefuroxime group. A, Overall; B, body mass index; C, diabetes; and D, bilateral ITA grafts.
ITA, Internal thoracic artery.
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FIGUREE3. Distribution of patient-specific optimal timing in vancomycin group. A, Overall; B, bodymass index; C, diabetes; D, bilateral ITA grafts. ITA,
Internal thoracic artery.
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TABLE E1. Risk factors associated with higher likelihood of wound
infection: cefuroxime group
Factor Estimate ± SE P
Reliability
(%)*
Overall
Diabetes 0.52  0.100 <.0001 94
History of PAD 0.32  0.099 .001 46
Previous stroke 0.46  0.13 .0006 87
Lower hematocrity 12  3.5 .001 82
Longer preoperative LOSz 0.11  0.049 .02 66
Complete heart block/pacer 0.45  0.203 .02 51
Previous MI 0.33  0.101 .0009 86
Higher number of ITA grafts 0.46  0.085 <.0001 100
Mitral valve procedure 0.55  0.11 <.0001 100
Pre-minimum phase
History of COPD 0.78  0.18 <.0001 73
Higher BUNx 0.069  0.021 .001 86
Post-minimum phase
Larger BMIjj 0.79  0.11 <.0001 76
Higher NYHA functional
class{
0.26  0.099 .009 90
SE, Standard error; PAD, pulmonary arterial disease; LOS, low output syndrome;MI,
myocardial infarction; ITA, internal thoracic artery; COPD, chronic obstructive pul-
monary disease; BUN, blood urea nitrogen; BMI, body mass index; NYHA,New York
Heart Association. *Percent of times factor appeared in 500 bootstrapped models
(based on 3 separate logistic models for each phase). y(1/hematocrit), inverse trans-
formation. zLog(preoperative LOSþ1), logarithmic transformation. x(BUN/20)2,
squared transformation. jjBMI/40), scaled transformation. {(1/NYHA functional
class), inverse transformation.
TABLE E2. Risk factors associated with higher likelihood of wound
infection: vancomycin group
Factor Estimate ± SE P
Reliability
(%)*
Overall
Diabetes 0.61 0.23 .007 84
History of COPD 0.57 0.23 .01 67
Dialysis 1.2  0.55 .03 84
Coronary artery diseasey
LAD 1.3  0.53 .01 94
LMT 0.55  0.23 .02 94
Emergency operation 1.3  0.47 .02 66
No history of hypertension 0.60  0.26 .02 61
Pre-minimum phase
Bilateral ITA grafts 2.7  0.71 .0001 81
Post-minimum phase
Higher BUNz 0.025  0.014 .07 83
Larger BMIx 0.75  0.36 .04 94
SE, Standard error; COPD, chronic obstructive pulmonary disease; LAD, left anterior
descending; LMT, left main trunk; ITA, internal thoracic artery; BUN, blood urea ni-
trogen; BMI, body mass index. *Percent of times factor appeared in 500 bootstrapped
models (based on 3 separate logistic models for each phase). yStenosis>0%. z(BUN/
20)2, squared transformation. x(BMI/40), scaled transformation.
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